business units
Multiple Sclerosis

It's not just about the products; it's about the way we interact with patients.
— Bill Sibold
SVP, Head of Multiple Sclerosis
We are committed to becoming a longterm partner to the MS community by working to deliver scientific advancements that will have a significant impact on the unmet needs of people living with MS.
Key Facts
Business Unit Head: William Sibold
Products Marketed (Worldwide):

AUBAGIO®

Driven by Science

Multiple sclerosis is a chronic disease that affects each person differently, with symptoms ranging from numbness in the limbs or forgetfulness to paralysis or loss of vision. MS is caused when the body’s immune system attacks the central nervous system, damaging the myelin sheath – the protective layer covering the nerves that carry signals between the brain and spinal cord and the rest of the body. Finding effective treatments for such a complex disease is no easy task, but our MS research is spearheaded by top experts employing some of the most advanced and creative scientific problem-solving skills in the industry.

For over a decade, Genzyme and our parent company Sanofi have each been working to develop novel treatments for MS. We have integrated these programs within Genzyme to establish ourselves as a leader in MS.

AUBAGIO ®(teriflunomide) is approved as a once-daily oral treatment for relapsing forms of MS. AUBAGIO is supported by a robust clinical program and has demonstrated significant efficacy in the three key measures for an MS treatment – reducing annualized relapse rate (ARR), delaying the progression of disability, and reducing MRI (magnetic resonance imaging) disease activity.

Our MS clinical pipeline includes the late-stage product candidate alemtuzumab. Alemtuzumab clinical studies researched a unique dosing regimen for relapsing MS. Alemtuzumab showed promise in head to head clinical studies against an approved MS therapy and could make a very important contribution to the treatment landscape. Alemtuzumab has completed phase 3 trials.

A Future Focusing on Repair

While many existing MS treatments modulate the disease’s symptoms, our focus is to research and develop future treatments that reset the damaged immune system. Our scientists are currently researching a small molecule that could actually repair the myelin sheath. This team is also studying whether alemtuzumab, which has completed phase 3 studies for relapsing/remitting MS, can effectively treat progressive MS, a much more advanced form of the disease.

Our Personalized Approach

Drawing on our vast experience in ultra-rare diseases, we recognize that truly personalized medicine involves developing relationships with patients and caregivers, health care providers, and disease organizations and foundations.

Though MS affects a much larger population than lysosomal storage disorders, we are building our MS business unit on the same core principle that guides our Rare Disease business unit: the importance of deeply understanding the experiences, challenges, and triumphs of those affected by MS. We aim to foster close connections with patients and their families to best understand their needs and to deliver services that have a positive impact.

Our MS leadership comprises experienced professionals with a strong foundation in MS. We have an exciting opportunity to draw on the diverse experiences of our MS team to forge a unique identity for Genzyme within the MS community.

Our Inspiration
Contact Us
Genzyme Corporation

500 Kendall Street
Cambridge, MA 02142
USA
T: 617-252-7500
F: 617-252-7600

Send Email
Jobs in Multiple Sclerosis
Career Opportunities

Building an exciting MS franchise, Genzyme has a need for qualified candidates to join our MS business unit.

Knowledge is Power
MS Atrium

We recognize that many people with MS desire to be their own advocates and take an active role in their treatment program. In order to provide both patients and physicians with cutting-edge, comprehensible resources about MS, we have sponsored an independent board of MS experts to help us create the interactive MS Atrium.

infoBox